Does the media prefer BEAM or EDIT?

In the previous week, Editas Medicine had 12 more articles in the media than Beam Therapeutics. MarketBeat recorded 22 mentions for Editas Medicine and 10 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 0.76 beat Beam Therapeutics' score of -0.13 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Editas Medicine. MarketBeat recorded 32 mentions for CRISPR Therapeutics and 22 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.50 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or EDIT?

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 22 articles in the media. Editas Medicine's average media sentiment score of 0.76 beat Intellia Therapeutics' score of -0.05 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or EDIT?

In the previous week, Editas Medicine had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Editas Medicine and 21 mentions for Lexicon Pharmaceuticals. Editas Medicine's average media sentiment score of 0.76 beat Lexicon Pharmaceuticals' score of 0.07 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer REPL or EDIT?

In the previous week, Replimune Group had 13 more articles in the media than Editas Medicine. MarketBeat recorded 35 mentions for Replimune Group and 22 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.76 beat Replimune Group's score of 0.37 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 9 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$2.88 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 09:05 AM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, LXRX, and REPL

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Lexicon Pharmaceuticals (LXRX), and Replimune Group (REPL). These companies are all part of the "biotechnology" industry.

How does Editas Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Editas Medicine	-157.32%	-196.63%	-38.17%

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.31	-$79.99M	-$0.86	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$0.75	N/A

In the previous week, Editas Medicine had 12 more articles in the media than Beam Therapeutics. MarketBeat recorded 22 mentions for Editas Medicine and 10 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 0.76 beat Beam Therapeutics' score of -0.13 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 78.31%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Beam Therapeutics beats Editas Medicine on 11 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Editas Medicine. MarketBeat recorded 32 mentions for CRISPR Therapeutics and 22 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.50 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus price target of $68.06, indicating a potential upside of 27.16%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's higher probable upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,474.32	-$581.60M	-$4.76	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$0.75	N/A

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Intellia Therapeutics currently has a consensus target price of $20.85, suggesting a potential upside of 74.66%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 22 articles in the media. Editas Medicine's average media sentiment score of 0.76 beat Intellia Therapeutics' score of -0.05 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	24.65	-$412.69M	-$3.36	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$0.75	N/A

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Editas Medicine	-157.32%	-196.63%	-38.17%

Summary

Intellia Therapeutics and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Lexicon Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Editas Medicine's net margin of -157.32%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Editas Medicine	-157.32%	-196.63%	-38.17%

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, indicating a potential upside of 84.21%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Lexicon Pharmaceuticals has higher revenue and earnings than Editas Medicine. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	22.07	-$50.34M	-$0.15	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$0.75	N/A

In the previous week, Editas Medicine had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Editas Medicine and 21 mentions for Lexicon Pharmaceuticals. Editas Medicine's average media sentiment score of 0.76 beat Lexicon Pharmaceuticals' score of 0.07 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexicon Pharmaceuticals beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Editas Medicine has higher revenue and earnings than Replimune Group. Editas Medicine is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$0.75	N/A

In the previous week, Replimune Group had 13 more articles in the media than Editas Medicine. MarketBeat recorded 35 mentions for Replimune Group and 22 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.76 beat Replimune Group's score of 0.37 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	9 Very Positive mention(s)	5 Positive mention(s)	15 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group presently has a consensus target price of $11.86, indicating a potential downside of 1.68%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.50
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Replimune Group has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Replimune Group's return on equity of -128.57% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Editas Medicine	-157.32%	-196.63%	-38.17%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Editas Medicine beats Replimune Group on 8 of the 15 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$281.98M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.84	9.02	270.57	25.05
Price / Sales	6.96	1,291.29	659.56	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	10.29	17.52	11.20	6.43
Net Income	-$160.06M	-$13.25M	$3.45B	$348.10M
7 Day Performance	8.68%	5.02%	3.39%	2.66%
1 Month Performance	-11.66%	-2.12%	-0.72%	-0.85%
1 Year Performance	30.32%	61.49%	77.42%	23.96%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	3.0489 of 5 stars	$2.88 flat	$5.40 +87.5%	+30.3%	$281.98M	$40.52M	N/A	230	Earnings Report Analyst Upgrade Analyst Revision Gap Up
BEAM Beam Therapeutics	2.2161 of 5 stars	$28.35 +9.4%	$46.85 +65.2%	+56.0%	$2.67B	$139.74M	N/A	510	Earnings Report Analyst Downgrade
CRSP CRISPR Therapeutics	3.2681 of 5 stars	$53.07 +7.1%	$68.11 +28.3%	-2.7%	$4.78B	$3.51M	N/A	460	Earnings Report Analyst Upgrade Analyst Revision
NTLA Intellia Therapeutics	3.2651 of 5 stars	$11.32 +5.1%	$20.19 +78.3%	+10.7%	$1.50B	$67.67M	N/A	600	Positive News Earnings Report Analyst Upgrade Analyst Revision
LXRX Lexicon Pharmaceuticals	1.5062 of 5 stars	$2.49 +6.9%	$4.55 +82.7%	+128.7%	$1.03B	$49.80M	N/A	140	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, LXRX, and REPL

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Lexicon Pharmaceuticals?

Summary

How does Editas Medicine compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, LXRX, and REPL

How does Editas Medicine compare to Beam Therapeutics?

Which has more risk & volatility, BEAM or EDIT?

Is BEAM or EDIT more profitable?

Do institutionals and insiders believe in BEAM or EDIT?

Which has stronger earnings & valuation, BEAM or EDIT?

Does the media prefer BEAM or EDIT?

Do analysts prefer BEAM or EDIT?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Do insiders & institutionals believe in CRSP or EDIT?

Does the media prefer CRSP or EDIT?

Which has more volatility & risk, CRSP or EDIT?

Do analysts recommend CRSP or EDIT?

Is CRSP or EDIT more profitable?

Which has better earnings & valuation, CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Do analysts recommend NTLA or EDIT?

Do institutionals & insiders have more ownership in NTLA or EDIT?

Does the media prefer NTLA or EDIT?

Which has more volatility and risk, NTLA or EDIT?

Which has preferable earnings & valuation, NTLA or EDIT?

Is NTLA or EDIT more profitable?

Summary

How does Editas Medicine compare to Lexicon Pharmaceuticals?

Which has more volatility & risk, LXRX or EDIT?

Do institutionals & insiders hold more shares of LXRX or EDIT?

Is LXRX or EDIT more profitable?

Do analysts rate LXRX or EDIT?

Which has better earnings and valuation, LXRX or EDIT?

Does the media prefer LXRX or EDIT?

Summary

How does Editas Medicine compare to Replimune Group?

Which has more risk and volatility, REPL or EDIT?

Which has higher valuation and earnings, REPL or EDIT?

Does the media prefer REPL or EDIT?

Do analysts rate REPL or EDIT?

Is REPL or EDIT more profitable?

Do insiders & institutionals hold more shares of REPL or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools